Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL7016 in Dry Eye Syndrome
NCT02092207Phase 2Completed
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Oct 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KL-7016 in dry eye syndrome (DED) (3 arms), sponsored by Yungjin Pharm. Co., Ltd. Primary endpoint: Change in corneal staining score at 12 weeks. Started Oct 2012; status: completed.
02
Drugs
KL-7016
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02092207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092207.